Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial

Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial

Abstract Background Central venous catheter (CVC) insertion is an important risk factor for venous thromboembolism (VTE) among patients with cancer. Routine use of primary thromboprophylaxis in this patient population is not currently recommended. We sought to assess the feasibility of conducting a...

Full description

Bibliographic Details
Main Authors: Rick Ikesaka, Deborah Siegal, Ranjeeta Mallick, Tzu‐Fei Wang, Deborah Witham, Carolyn Webb, Marc Carrier, for the Canadian Venous Thromboembolism Research Network (CanVECTOR)
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
hemorrhage
neoplasia
rivaroxaban
venous thromboembolism
venous thrombosis
Online Access:https://doi.org/10.1002/rth2.12517

Internet

https://doi.org/10.1002/rth2.12517

Similar Items